Key result
TLR4 inhibition emerges as a potential strategy to prevent doxorubicin-induced cardiac inflammation and cardiotoxicity.
Why the study?
The underlying mechanisms of doxorubicin-induced cardiotoxicity remain incompletely understood, and there are no established therapeutic guidelines.
What is the role of the TLR4 signaling pathway in doxorubicin-induced cardiotoxicity and cardiac inflammation?
What is the role of the TLR4 signaling pathway in doxorubicin-induced cardiotoxicity and cardiac inflammation?
Understanding the TLR4 signaling pathway's role in doxorubicin-induced cardiac inflammation may help develop therapeutic strategies for cardiotoxicity.
TLR4 inhibition merits trial evaluation for doxorubicin cardiotoxicity prevention; hypothesis-generating from Level 5 evidence and should not yet change practice.
Doxorubicin (Dox) is one of the most frequently used chemotherapeutic drugs in a variety of cancers, but Dox-induced cardiotoxicity diminishes its therapeutic efficacy. The underlying mechanisms of Dox-induced cardiotoxicity are still not fully understood. More significantly, there are no established therapeutic guidelines for Dox-induced cardiotoxicity. To date, Dox-induced cardiac inflammation is widely considered as one of the underlying mechanisms involved in Dox-induced cardiotoxicity. The Toll-like receptor 4 (TLR4) signaling pathway plays a key role in Dox-induced cardiac inflammation, and growing evidence reports that TLR4-induced cardiac inflammation is strongly linked to Dox-induced cardiotoxicity. In this review, we outline and address all the available evidence demonstrating the involvement of the TLR4 signaling pathway in different models of Dox-induced cardiotoxicity. This review also discusses the effect of the TLR4 signaling pathway on Dox-induced cardiotoxicity. Understanding the role of the TLR4 signaling pathway in Dox-induced cardiac inflammation might be beneficial for developing a potential therapeutic strategy for Dox-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Sumneang et al. (2023) conducted a review in Doxorubicin-induced cardiotoxicity. Toll-like receptor 4 (TLR4) inhibition was evaluated. The Toll-like receptor 4 (TLR4) signaling pathway plays a key role in doxorubicin-induced cardiac inflammation, making TLR4 inhibition a potential therapeutic strategy for preventing cardiotoxicity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: